DENOVO BIOPHARMA LLC
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
17
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials
A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 197
- Registration Number
- NCT05113771
- Locations
- 🇺🇸
University of Alabama at Birmingham, Huntsville, Alabama, United States
🇺🇸Alea Research, Phoenix, Arizona, United States
🇺🇸Collaborative Neuroschience Research, LLC, Garden Grove, California, United States
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 260
- Registration Number
- NCT03776071
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Mayo Clinic - Arizona, Scottsdale, Arizona, United States
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Other: R-CHOP + placebo
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 256
- Registration Number
- NCT03263026
- Locations
- 🇺🇸
Oncology Specialties: Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸Central Arkansas Radiation Therapy Institute, Little Rock, Arkansas, United States
A Study of LY2140023 in Healthy Participants
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Denovo Biopharma LLC
- Registration Number
- NCT01659177
- Locations
- 🇨🇭
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Allschwil, Switzerland
A Study of LY2140023 in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 18
- Registration Number
- NCT01637142
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- Next
News
Denovo Biopharma Out-Licenses Biomarker-Guided Depression Drug DB104 to Taiwan Partner
Denovo Biopharma has granted exclusive rights to develop and commercialize DB104 (liafensine) in Taiwan to Chuang Yi Global Asset Management Co., Ltd.